Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey

Fausto Roila1, Enzo Ballatori2, Roberto Labianca3, Filippo De Braud4, Karen Borgonovo5, Olga Martelli6, Ciro Gallo7, Angelo Tinazzi8, and Francesco Perrone9, on behalf of the Italian Medical Oncology Association (AIOM)*

1Medical Oncology Division, S. Maria Hospital, Terni; 2Dept of Internal Medicine and Public Health, University of L’Aquila, L’Aquila; 3Dept of Medical Oncology, Bergamo; 4European Institute of Oncology, Milan; 5Dept of Oncology, Fatebenefratelli Hospital, Milan; 6Dept of Oncology, S. Giovanni Hospital, Rome; 7Dept of Medicine and Public Health, 2nd University of Naples, Naples; 8Medical Informatics and Biometry Unit, Sendo Tech, Milan; 9National Cancer Institute, Naples, Italy. *Investigators and participating centers are reported in the Appendix

ABSTRACT

Aims and background. An appropriate use of drugs should follow the registered indications. Different reasons can induce oncologists to prescribe drugs off-label. The aim of this study was to describe incidence and characteristics of these prescriptions in Italy.

Methods. Patients submitted to chemotherapy in 15 Italian oncology centers were evaluated for two randomized non-consecutive days of two weeks in May 2006.

Results. The study enrolled 644 patients receiving 1,053 drugs. Overall, 199 of 1053 (18.9%) prescriptions were off-label. In 92 of 199 cases (46.2%), the drugs were used for a neoplasm for which they were not approved, but there was scientific evidence (one or more randomized clinical trials or more phase II studies published in a major oncology journal) justifying the prescription. In 27 cases (13.6%), the drugs were prescribed for a rare neoplasm (cisplatin and gemcitabine in mesothelioma). In 20/21 cases (10.1%/10.5%), drugs were used in association/alone in contrast with the approved use (capecitabine in association in colorectal cancer). In 28/11 cases (14.0%/5.6%), the drugs were used in lines of chemotherapy subsequent/previous to that approved.

Conclusions. Off-label use of antineoplastic drugs, in this observational survey, represents less than 20% of the prescriptions, and most of them are based on scientific evidence of efficacy.

Key words: antineoplastic agents, chemotherapy, off-label.

Acknowledgments: We thank Mrs Elena Moro, AIOM secretariat, for her support in the study organization.

Correspondence to: Fausto Roila, MD, Medical Oncology Division, S. Maria Hospital, 05100 Terni, Italy. Tel +39 0744205410; fax +39 0744205632; e-mail roila.fausto@libero.it

Received December 1, 2008; accepted May 14, 2009.